Drugs / MDR-001
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07550634 | Jun → Jul 2026 overdue | liver disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07550621 | May 2026 overdue | — | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07110766 | Aug → Sep 2025 overdue | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06778850 | Jun 2023 → Jul 2025 overdue | — | MindRank AI Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06606483 | Sep 2024 → Jul 2025 overdue | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07274137 | Feb 2026 → Jun 2027 expected | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDR-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07110766 ↗ |
| Action | Activate | “GLP-1 receptor agonist” NCT07550621 ↗ |
| Modality | Small molecule | “small molecule MDR-001 tablets” NCT06606483 ↗ |
| Route | Oral | “Administered orally” NCT06606483 ↗ |